MicroRNA-100 and microRNA-21 as markers of survival and chemotherapy response in pancreatic ductal adenocarcinoma UICC stage II

Table 1 Clinicopathologic characteristics of PDAC stage II patients

	patients n	Median overall survival (months)	95 % CI	p
Total	91	21	16–26
Age (years)
≤65	41	27	21–33	0.1754
>65	50	19	16–22
Gender
Female	41	26	18–34	0.8796
Male	50	20	15–25
UICC stage
IIa	29	27	13–40	0.3347
IIb	62	20	16–24
Grading
G1 and G2	55	26	1–31	0.0474
G3	36	15	8–22
Perineural invasion
Pn0	32	19	9–29	0.7835
Pn1	59	21	16–26
Vene invasion
V0	74	23	16–30	0.5583
V1	17	21	17–25
Lymphatic invasion
L0	50	24	18–29	0.9821
L1	41	21	15–26
Resection margin
R0	77	23	15–31	0.3653
R1	24	18	16–26
Type of surgery
Pancreatic head resection	75	32	17–25	0.2475
Traverso-Longmire	66
Whipple-Kausch	9
Pancreatic left resection	16	21	14–49
Adjuvant gemcitabine
Yes	64	31	24–37	2.9922E-8
No	27	12	9–14

Indication of median overall survival in months and 95 % confidence interval (CI). p < 0.05 indicates significance

ISSN: 1868-7083